NSCLC: Contemporary Insights
Survival in T3 NSCLC May Differ With Chest Wall Infiltration
This retrospective analysis found that overall survival in NSCLC was significantly worse among patients with T3 tumors characterized by parietal pleura infiltration or chest wall infiltration than those characterized by size or the presence of a separate tumor nodule in the same lobe.
Recurrent Metastatic NSCLC vs De Novo Stage IV: How Do Survival Rates Compare?
A study found that patients with distant recurrent metastatic non-small cell lung cancer had significantly better overall survival than those with de novo stage IV disease. These results may help inform clinical trial designs to ensure balanced baseline characteristics.
Detecting Lung Cancer: Is This A Better Way?
A lung cancer screening test examining small noncoding RNAs has demonstrated the ability to identify lung cancer using whole blood collected in the clinical setting, making it a potential alternative to low-dose computed tomography.
NSCLC: Sociodemographic Factors That Predict Neoadjuvant Therapy
Neoadjuvant chemoimmunotherapy may be limited in use and accessibility. These researchers analyzed the potential barriers, including socioeconomic status, geographical location, and insurance status.
ICI Therapy for NSCLC: Duration of Treatment and Overall Survival
A landmark analysis suggests that limiting immune checkpoint inhibitor (ICI)-based treatment to 2 years confers the same survival benefit as extended treatment for advanced non-small cell lung cancer.
In Early NSCLC, Genetic Signature Predicts Recurrence After Radiation
A PI3K gene signature measuring PI3K‐AKT pathway activation may help select appropriate candidates for stereotactic body radiation therapy, suggest the results of a new study.
Is Systemic Therapy Underused in NSCLC Patients Undergoing Pneumonectomy? Maybe…
Recent approvals of immunotherapy agents for adjuvant and neoadjuvant therapy may support wider use among patients with non-small cell lung cancer treated with pneumonectomy.